Literature DB >> 21326278

Pharmacotherapy: GLP-1 analogues and insulin: sound the wedding bells?

Michael A Nauck, Juris J Meier.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21326278     DOI： 10.1038/nrendo.2011.30

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  10 in total

1.  Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.

Authors:  John B Buse; Richard M Bergenstal; Leonard C Glass; Cory R Heilmann; Michelle S Lewis; Anita Y M Kwan; Byron J Hoogwerf; Julio Rosenstock
Journal:  Ann Intern Med       Date:  2010-12-06       Impact factor: 25.391

Review 2.  The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

Authors:  Daniel J Drucker; Michael A Nauck
Journal:  Lancet       Date:  2006-11-11       Impact factor: 79.321

3.  Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

Authors:  John B Buse; Julio Rosenstock; Giorgio Sesti; Wolfgang E Schmidt; Eduard Montanya; Jason H Brett; Marcin Zychma; Lawrence Blonde
Journal:  Lancet       Date:  2009-06-08       Impact factor: 79.321

4.  Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes.

Authors:  Helle Linnebjerg; Soomin Park; Prajakti A Kothare; Michael E Trautmann; Kenneth Mace; Mark Fineman; Ian Wilding; Michael Nauck; Michael Horowitz
Journal:  Regul Pept       Date:  2008-07-16

5.  Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study.

Authors:  Sabine Arnolds; Sibylle Dellweg; Janina Clair; Marie-Paule Dain; Michael A Nauck; Klaus Rave; Christoph Kapitza
Journal:  Diabetes Care       Date:  2010-03-31       Impact factor: 17.152

6.  Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM.

Authors:  K Cusi; G R Cunningham; J P Comstock
Journal:  Diabetes Care       Date:  1995-06       Impact factor: 19.112

7.  Nocturnal glucose metabolism after bedtime injection of insulin glargine or neutral protamine hagedorn insulin in patients with type 2 diabetes.

Authors:  Thomas Linn; Britta Fischer; Nedim Soydan; Michael Eckhard; Julia Ehl; Clemens Kunz; Reinhard G Bretzel
Journal:  J Clin Endocrinol Metab       Date:  2008-07-08       Impact factor: 5.958

8.  Three-year efficacy of complex insulin regimens in type 2 diabetes.

Authors:  Rury R Holman; Andrew J Farmer; Melanie J Davies; Jonathan C Levy; Julie L Darbyshire; Joanne F Keenan; Sanjoy K Paul
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

9.  Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  D M Nathan; J B Buse; M B Davidson; E Ferrannini; R R Holman; R Sherwin; B Zinman
Journal:  Diabetologia       Date:  2008-10-22       Impact factor: 10.122

10.  Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.

Authors:  D Russell-Jones; A Vaag; O Schmitz; B K Sethi; N Lalic; S Antic; M Zdravkovic; G M Ravn; R Simó
Journal:  Diabetologia       Date:  2009-08-14       Impact factor: 10.122
  10 in total
  6 in total

Review 1.  Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making.

Authors:  Gerhard H Scholz; Holger Fleischmann
Journal:  Ther Adv Endocrinol Metab       Date:  2014-10       Impact factor: 3.565

Review 2.  Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance.

Authors:  Sri Harsha Tella; Marc S Rendell
Journal:  Ther Adv Endocrinol Metab       Date:  2015-06       Impact factor: 3.565

3.  The Future of Combination Therapies of Insulin with a Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes - Is it Advantageous?

Authors:  Baptist Gallwitz
Journal:  Eur Endocrinol       Date:  2014-08-28

Review 4.  GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.

Authors:  Juris J Meier
Journal:  Nat Rev Endocrinol       Date:  2012-09-04       Impact factor: 43.330

Review 5.  GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.

Authors:  Michael A Nauck; Daniel R Quast; Jakob Wefers; Juris J Meier
Journal:  Mol Metab       Date:  2020-10-14       Impact factor: 7.422

Review 6.  Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature.

Authors:  R Balena; I E Hensley; S Miller; A H Barnett
Journal:  Diabetes Obes Metab       Date:  2012-11-12       Impact factor: 6.577
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.